Vellabio
Worcester, US · Founded 2020 · 12 employees on LinkedIn · 1 known investors
Vella Bioscience develops products for women's sexual and reproductive health using nano-encapsulated liposomal cannabidiol and liposome-based biotech to improve absorption of active ingredients, with a focus on female arousal, orgasm, and related pain. Its work spans the broader landscape of women's sexual and reproductive medicine.
Founders & leadership
Vellabio was founded in 2020 by Nial C. DeMena.
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 1 round · 2020
▶$1.6MraisedDec 2020 · 11 investors · BiotechnologyRule 506(b)
▶$1.6MraisedDec 2020 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Harin Padma-NathanExecutive Officer, Director
- Carolyn WheelerExecutive Officer
- Michael FridExecutive Officer
- Nial C. DeMenaExecutive Officer, Director, Promoter
- Julio VegaExecutive Officer
- Offering amount
- $5.5M
- Amount sold
- $1.6M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Vellabio do?
- Vella Bioscience develops products for women's sexual and reproductive health using nano-encapsulated liposomal cannabidiol and liposome-based biotech to improve absorption of active ingredients, with a focus on female arousal, orgasm, and related pain. Its work spans the broader landscape of women's sexual and reproductive medicine.
- Who founded Vellabio?
- Vellabio was founded by Nial C. DeMena in 2020.
- Who are Vellabio's investors?
- Vellabio's investors include Merida Capital Holdings.
- How much funding has Vellabio raised?
- Vellabio has disclosed $1.6M raised across 1 round.
- Where is Vellabio headquartered?
- Vellabio is headquartered in Worcester, US.